FAQ/Help |
Calendar |
Search |
Today's Posts |
08-11-2014, 10:54 PM | #1 | |||
|
||||
Senior Member
|
http://www.ny1.com/content/lifestyle...son-s-disease/
Austrian biotech company AFFiRis AG announced positive results of a phase one safety study for a vaccine that could slow or even stop the progression of Parkinson's.
__________________
In the last analysis, we see only what we are ready to see, what we have been taught to see. We eliminate and ignore everything that is not a part of our prejudices. ~ Jean-Martin Charcot The future is already here — it's just not very evenly distributed. William Gibson |
|||
Reply With Quote |
08-12-2014, 05:59 PM | #2 | ||
|
|||
Member
|
Quote:
|
||
Reply With Quote |
"Thanks for this!" says: | Lemonlime (08-14-2014) |
08-12-2014, 07:14 PM | #3 | ||
|
|||
Member
|
Quote:
Alternatively, you can also consider the currently recruiting study for Prothena ( http://ir.prothena.com/releasedetail...leaseID=863495 ). They are also conducting research on an a-syn antibody. Although it's only a phase 1 study, some researchers I've spoken with are more impressed with their drug and methodology than AffiRis. As the trial has just begun, it will probably go on for at least a year, so you have some time before you would need to join. In addition, even if you were to wait for a possible phase 2, it will certainly be less than 6 years. In most of the trials, your odds of getting the drug as opposed to a placebo will probably be 2 -1 or 3 -1. I, along with several other members on this board, have had discussions with the trial teams about Prothena's drug PRX002. We will watch it closely, see how the trial proceeds, and make some decisions later. I suggest considering this approach for two reasons. First, we need volunteers for PD trials worldwide if we ever want to see drugs go through the long research process prior to filing an NDA and receiving approval. Second, if you are going to take a shot at a neuroprotective antibody, I would think you would want to do so with one that has some degree of real science behind it, positive pre-clinical research, and positive phase 1 safety studies. As opposed to a natural analog, if one exists, that no one has the slightest idea about how it would function. These are monoclonal antibodies that may have effects on the body and other proteins that we are not aware of at this time. Gary |
||
Reply With Quote |
08-13-2014, 10:29 AM | #4 | |||
|
||||
Member
|
While we are waiting... and waiting...and waiting, there is
Baikal (Chinese) Skullcap. http://onlinelibrary.wiley.com/doi/1...201000604/full. Swanson has it, Curcumin http://pubs.acs.org/doi/abs/10.1021/cn3001203 I use www.longvida.com which is highly bioavailable. It works well with beta cyclodextrin but I don't know where to find that. http://pubs.acs.org/doi/abs/10.1021/bi500642f and as previously posted by Conductor71. http://www.ncbi.nlm.nih.gov/pmc/arti...4/?tool=pubmed, serotonin is important. That might be why Dr. Hinz emphasizes balancing serotonin and why he says his protocol stops progression (that and addressing the glutathione deficiency.)
__________________
Born 1948. Diagnosed 2011. DBS ON 7/17. Taking cd/ld 200 MG at 6 am, 9 am, 12 pm, 3 pm, 6 pm and 9 pm. Finasteride 5 mg, Life Extension Mix and Once-Daily Health Booster, Mitochondrial Energy Optimizer with BioPQQ, Optimized Curcumin (longvida), Triple Action Cruciferous Vegetable Extract with Resveratrol, Vectomega-3, Vit D3 5000U,Lithium orotate 5 mg, AMPK Activator, Kefiran, N-Acetyl-L- Cysteine (NAC), Tri-Magnesium, Advanced NeuroPro, Duozyme, Palmitoylethanolamide (PEA) Updated 9/21/17. Last edited by GerryW; 08-13-2014 at 10:44 AM. Reason: additional info |
|||
Reply With Quote |
"Thanks for this!" says: | FVDB (03-25-2015) |
08-13-2014, 11:25 AM | #5 | ||
|
|||
Member
|
Quote:
|
||
Reply With Quote |
08-13-2014, 06:41 PM | #6 | ||
|
|||
Member
|
|
||
Reply With Quote |
"Thanks for this!" says: | Lemonlime (08-14-2014) |
03-25-2015, 01:30 PM | #7 | ||
|
|||
New Member
|
Hello from France,
Any news from this Prothena study? Thanks. |
||
Reply With Quote |
03-25-2015, 01:40 PM | #8 | ||
|
|||
Member
|
|
||
Reply With Quote |
03-25-2015, 01:48 PM | #9 | ||
|
|||
Member
|
Yes, the Phase 1 results reported were great. Dramatic reduction in free serum alpha-synuclein along with a very good safety profile (well tolerated) with just one dose. Of course, we still need to see if a reduction in a-syn will actually lead to a slowing, stopping or reversal of the disease. That won't be known until they report some interim results from the ongoing phase 2 study.
http://ir.prothena.com/releasedetail...leaseID=902569 |
||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
Ultra-high-field MRI may allow earlier diagnosis of Parkinson's disease | Parkinson's Disease | |||
Parkinson’s Disease Vaccine Study Enrolls First Patients | Parkinson's Disease | |||
Parkinson's disease patients contain high amount of beta-HCH pesticide | Parkinson's Disease | |||
Parkinson’s Vaccine Being Tested in Houston | Parkinson's Disease | |||
High Cholesterol Can Increase Risk of Parkinson's Disease | Parkinson's Disease |